另一种药物在慢性乙型肝炎患者中显示功能性治愈潜力
Another Drug Shows Potential for Functional Cures in Chronic Hepatitis B
一项二期研究显示,高剂量siRNA疗法HRS-5635在慢性乙型肝炎患者中实现功能性治愈的比例为19%,为治疗提供了新思路。
研究显示高剂量siRNA疗法在慢性乙型肝炎患者中实现功能性治愈的比例较高,为治疗提供了新思路。
— With highest dose of siRNA therapy, 19% achieved a functional cure 24 weeks after treatment ended
November 10, 2026 • 3 min read
Reductions in hepatitis B surface antigen (HBsAg) were observed with a novel small interfering RNA (siRNA) therapy in patients with chronic hepatitis B virus (HBV) infection, according to a phase II study.
Among patients randomized to monotherapy with one of four doses of the siRNA HRS-5635, all 32 on the highest dose (400 mg) had HBsAg levels less than 100 IU/mL after 48 weeks of treatment, with 88% still at that level 24 weeks after treatment ended.
Among this high-dose group, 16% achieved a functional cure, with an HBsAg clearance level of less than 0.05 IU/mL after 48 weeks -- a percentage that rose to 19% by 24 weeks post-treatment, reported Xieer Liang, PhD, of Southern Medical University in Guangzhou, China, at the American Association for the Study of Liver Diseases annual meeting in Denver.
"A dose-dependent antiviral response was observed with HRS-5635," Liang said. "All HRS-5635 regimens were generally safe and well-tolerated."
An estimated 240 million people worldwide have chronic HBV infection, including about 640,000 U.S. adults. Chronic HBV can cause liver damage, cirrhosis, liver cancer, and death. Five antivirals and two immune modulators are approved in the U.S. to treat chronic HBV, with treatment regimens lasting from 6 months to over 1 year.
In a previous phase II trial, siRNA therapy with an immunomodulator reduced HBsAg in patients with chronic HBV infection. Last month, the FDA approved another nucleic acid-based therapeutic, the antisense oligonucleotide drug bepirovirsen (Hibsago), for patients with chronic HBV taking antiviral therapy based on results from the B-Well 1 and B-Well 2 studies. In those trials, 19% to 20% of patients with HBsAg levels between 100 and 3,000 IU/mL had a functional cure with bepirovirsen at week 72.
The current trial included patients with chronic HBV on stable nucleos(t)ide analogue therapy who had HBsAg levels over 100 and less than 3,000 IU/mL and HBV DNA levels less than 20 IU/mL. Patients could be hepatitis B envelope antigen (HBeAg) positive or negative, but they couldn't have cirrhosis. All patients received tenofovir amibufenamide during 48 weeks of HRS-5635 treatment.
Mean age ranged from 41.5 to 44.6 years in the four treatment groups, 59.4% to 76.7% were men, and mean HBsAg ranged from 1,058.2 IU/mL to 1,200.4 IU/mL. Most patients were HBeAg negative (65.6% to 73.3%).
The investigators defined functional cure as sustained HBV DNA suppression and HBsAg clearance of less than 0.05 IU/mL, with or without seroconversion, sustained for 24 weeks after treatment.
All four HRS-5635 doses achieved the study's primary endpoint of HBsAg reduction from baseline to week 12, with mean reductions of -1.26 log10 IU/mL in the 50-mg group, -1.90 log10 IU/mL in the 100-mg group, -1.99 log10 IU/mL in the 200-mg group, and -2.12 log10 IU/mL in the 400-mg group.
Among patients in the 400-mg group, 45% converted from HBeAg positive to HBeAg negative after 48 weeks of treatment, a percentage that slid to 27% at 24 weeks after treatment.
In patients receiving the 400-mg dose who were HBeAg negative and had HBsAg below 1,000 IU/mL at baseline, 33% reached the functional cure rate of HBsAg less than 0.05 IU/mL.
Across the four groups, 46.9% to 60% had a treatment-related adverse event. There were only two such events that were grade 3 or higher, and no serious adverse events related to treatment and no deaths occurred. Upper respiratory tract infections were the most common adverse event, occurring in 25% to 33.3% of patients in the four groups.
Alanine transaminase elevations occurred in up to 6.7% of patients during and after treatment, Liang said, but levels were generally stable during treatment, and no elevations reached a grade 3 level.
The follow-up period of 24 weeks after treatment ended was relatively short, Liang cautioned, but a longer-duration extension study is ongoing, along with a phase III trial.
来源:MedPage Today · medpagetoday.com